Amgen scores FDA's 'breakthrough' nod for prospective leukemia therapy

Amgen ($AMGN) nabbed a breakthrough designation for its mid-stage blood cancer drug blinatumomab, which delivered promising Phase II data in adults with two specific types of acute lymphoblastic leukemia. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.